CEST at 3.5 ppm demonstrated hyperintensity in IDH-wild type when compared with IDH-mutant glioma patients, along with a high level of relative CBV [16,22,29], while showed no significant differences regarding the MGMT promoter methylation status [22]. The gene discussed is IDH1; the disease is central nervous system cancer.